S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML

• H. Erba,
• P. Montesinos,
• R. Vrhovac,
• E. Patkowska,
• H.-J. Kim,
• P. Zak,
• P.-N. Wang,
• T. Mitov,
• J. Hanyok,
• L. Liu,
• A. Benzohra,
• A. Lesegretain,
• J. Cortes,
• A. Perl,
• M. Sekeres,
• H. Dombret,
• S. Amadori,
• J. Wang,
• M. Levis,
• R. Schlenk

Affiliations

H. Erba

1 Duke Cancer Institute, Durham, NC, United States of America

P. Montesinos

2 La Fe University and Polytechnic Hospital, Valencia, Spain

R. Vrhovac

3 University Hospital Centre Zagreb, Zagreb, Croatia

E. Patkowska

4 Institute of Hematology and Blood Transfusion, Warsaw, Poland

H.-J. Kim

5 The Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, South Korea

P. Zak

6 University Hospital Hradec Kralove, Hradec Kralove, Czechia

P.-N. Wang

7 Chang Gung Medical Foundation, Linkou, Taiwan

T. Mitov

8 Daiichi Sankyo UK Ltd, Uxbridge, United Kingdom

J. Hanyok

9 Daiichi Sankyo, Inc, Basking Ridge, NJ

L. Liu

9 Daiichi Sankyo, Inc, Basking Ridge, NJ

A. Benzohra

9 Daiichi Sankyo, Inc, Basking Ridge, NJ

A. Lesegretain

9 Daiichi Sankyo, Inc, Basking Ridge, NJ

J. Cortes

10 Augusta University Medical Center, Augusta, GA

A. Perl

11 University of Pennsylvania, Philadelphia, PA

M. Sekeres

12 University of Miami Health System, Miami, FL, United States of America

H. Dombret

13 Saint Louis Hospital, University of Paris, Paris, France

S. Amadori

14 Tor Vergata Polyclinic Hospital Rome, Rome, Italy

J. Wang

15 Institute of Hematology and Blood Diseases Hospital, Tianjin, China

M. Levis

16 Johns Hopkins University, Baltimore, MD, United States of America

R. Schlenk

17 Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany